^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
A summary of management strategies for recurrent and/or metastatic SCCHN...No platinum-based ChT during the last 6 months and PD-L1-positive tumour...Options...Platinum/5-FU/cetuximab if contraindication to immunotherapy and fit for platinum-based therapy...
